Skip to Main Content
Skip Nav Destination

Regulatory T cells Inhibit CAR T-cell Activity via the BTLA–HVEM Axis

June 17, 2024

Major Finding: The BTLAHVEM immune checkpoint suppresses CAR T-cell activation and therapeutic effector function.

Concept: BTLA binds HVEM on regulatory T cells and recruits SHP-1/2 phosphatases to inhibit CAR T-cell signaling.

Impact: Targeting BTLA may improve the efficacy of CAR T-cell immunotherapy in cancers with high HVEM expression.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal